[Undesired cutaneous adverse drug reactions: What is new?].
New therapeutic agents, i.e., biologicals, may induce a variety of novel cutaneous adverse reactions (CAR), which hardly can be assigned to existing classification systems. Basing on clinical examples, we present a recently established classification system for CAR to novel drugs. In addition, management strategies for CAR to tumor necrosis factor-α antagonists and to epidermal growth factor receptor inhibitors are discussed.